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Abstract
Purpose of Review This study reviews the available literature to compare the accuracy of areal bonemineral density derived from
dual X-ray absorptiometry (DXA-aBMD) and of subject-specific finite element models derived from quantitative computed
tomography (QCT-SSFE) in predicting bone strength measured experimentally on cadaver bones, as well as their clinical
accuracy both in terms of discrimination and prediction. Based on this information, some basic cost-effectiveness calculations
are performed to explore the use of QCT-SSFE instead of DXA-aBMD in (a) clinical studies with femoral strength as endpoint,
(b) predictor of the risk of hip fracture in low bone mass patients.
Recent Findings Recent improvements involving the use of smooth-boundary meshes, better anatomical referencing for
proximal-only scans, multiple side-fall directions, and refined boundary conditions increase the predictive accuracy of QCT-
SSFE.
Summary If these improvements are adopted, QCT-SSFE is always preferable over DXA-aBMD in clinical studies with femoral
strength as the endpoint, while it is not yet cost-effective as a hip fracture risk predictor, although pathways that combine both
QCT-SSFE and DXA-aBMD are promising.
Keywords Hip fracture . Computed tomography . Subject-specific finite element models . Cost-benefit
Introduction
According to the standard of care accepted in most countries, the
risk for a given patient to experience a fragility hip fracture is
determined indirectly by measuring the areal bone mineral den-
sity (aBMD) at the hip region using dual X-ray absorptiometry
(DXA). This information is then combined with clinical risk
factors (such as age, gender, weight, height, previous fractures,
smoking, etc.) in epidemiological models such as FRAX that
provide an estimate of the absolute risk of fracture over 5 or
10 years [1]. Approximately half of the patients who face a hip
fracture are considered at low risk with these risk predictors [2].
This alone would suggest that we need better ways to estimate
the risk of hip fracture in fragile elderlies.
The strength of a bone (the intensity of the force loading the
bone in a certain direction that is required to fracture it) can be
measured only invasively and destructively. However, since
1985 when it was first described in the literature [3], consid-
erable effort has been spent in developing subject-specific
finite element models derived from quantitative computed to-
mography (QCT-SSFE) to predict non-invasively bone
strength. Today QCT-SSFE can predict such strength with
excellent accuracy, possibly higher than that provided by hip
DXA-aBMD [4]. If this is true, the strength estimated by
QCT-SSFE models should provide a better predictor of the
hip fracture risk assessment, compared to the current standard
of care, DXA-aBMD.
Despite this, in a paper reporting the conclusions of the
International Society for Clinical Densitometry (ISCD) 2015
Position Development Conference [5], Zysset et al. wrote:
“Femoral strength as estimated by QCT-based FEA is compa-
rable to hip DXA for prediction of hip fractures in
This article is part of the Topical Collection on Biomechanics
* Marco Viceconti
m.viceconti@Sheffield.ac.uk
1 Department of Mechanical Engineering, University of Sheffield,
Sheffield, UK
2 INSIGNEO Institute for in silico Medicine, University of Sheffield,
Sheffield, UK
3 Insigneo Institute for in silico medicine, University of Sheffield, Pam
Liversidge Building, Sheffield S13JD, UK
Current Osteoporosis Reports (2018) 16:216–223
https://doi.org/10.1007/s11914-018-0438-8
postmenopausal women and older men”. In the rationale,
while they acknowledged that “From biomechanical tests
in vitro, FEA is overall a better surrogate of spine and hip
failure load than DXA aBMD”, the results published up to
2014 [6–10] could not find significant differences between
QCT-SSFE strength and DXA-aBMD in discriminating be-
tween fractured and non-fractured patients. More recent stud-
ies propose methodological improvements that may modify
these conclusions [11••, 12••]. However, even in that case it is
unclear if such differences are large enough to justify, for each
possible clinical use case, a change of technology.
The aim of the present study is to review the most recent
relevant literature to establish if, and under which conditions,
it is convenient (in terms of effectiveness, cost, risk, and avail-
ability) to replace the current DXA-aBMD as a predictor of
the risk of hip fracture with the femoral strength predicted by
QCT-SSFE models.
Due to space limitations, in this review, we will not consider a
third approach, where subject-specific finite element models are
generated from DXA images (DXA-SSFE) [13, 14]. This meth-
od has an accuracy in predicting hip strength somehow interme-
diate between DXA-aBMD and QCT-SSFE [15].
Accuracy of DXA-aBMD vs QCT-SSFE in Predicting
Bone Strength
QCT-SSFE models can accurately predict the deformation
induced in a cadaveric femur by any loading. In an extensive
study where over 600 independent bone deformation mea-
surements were made, QCT-SSFE models generated using a
modelling technology (hereinafter referred to as CT2S) were
found to predict the deformation of human femurs (induced by
external loads) with a root mean squared error (normalised by
the peak measured strain) of only 7% [16]. Considering the
complexity of biomechanical deformation of mineralised tis-
sues, it seems unlikely that much higher predictive accuracies
can be expected in the future. Since aBMD cannot be used to
predict strains, no comparison is possible for this indicator.
When QCT-SSFE models were used to predict the strength
of human cadaver femurs, there is no consensus in the litera-
ture on how to express the predictive accuracy. Since the mea-
sured and the predicted values express the same quantity using
the same unit of measurement, a good representation of aver-
age error of the predictor is the Standard Error of the Estimate
of the linear regression between measured and predicted
values, normalised by the average measured strength
(%SEE). When the results are analysed with this error estima-
tor, four validation studies published by four research groups
using different but similar QCT-SSFE modelling technologies
published in the last 6 years, involving 184 cadaveric femurs,
reported a %SEE between 15 and 16% [4, 17–19]. Given all
these models used strain as a predictor of fracture, and that
fracture is a much more complex phenomenon to predict than
strain, an error in predicting strength that is double of that for
predicting strain seems reasonable and difficult to reduce sig-
nificantly any further in the future.
As aBMD measurements are only indirect predictors of
strength, the error metric most comparable to the %SEE used
for QCT-SSFE models is probably the standard error of the
Regression (%SER) between the measured strength and mea-
sured aBMD, again normalised by the average measured
strength. Looking at five large studies [4, 20–23], the average
error of aBMD as predictor of femoral strength, as measured by
%SER over 300 femurs was on average 22% (range 19–23%).
These results suggest that QCT-SSFE can predict femoral
strength from QCT images with an accuracy that is 6–7 pp.1
higher than that provided by aBMD. The good reproducibility
of the error estimate for both QCT-SSFE and DXA-aBMD
between research groups suggest the methods are reasonably
mature.
One possible additional improvement is to account for the
tissue anisotropy (which is not detectable at the resolution of
clinical QCT) using a population-based statistical atlas obtain-
ed with high-resolution micro-CT imaging on cadaveric bones
[24]. A recent study [25] suggested that this approach could
improve the average accuracy of QCT-SSFE to predict bone
strength by another 3 pp (compared to %SEE of 15–16%
without anisotropy). This modification would bring the im-
provement of QCT-SSFE over aBMD to a significant 10 pp.
However, the study did not calculate the accuracy against
experimental results, but against the prediction of another FE
model generated from higher resolution data. Thus, while this
approach is promising, for the time being the clinical accuracy
of QCT-SSFE methods in predicting bone strength should be
considered to be 6–7 pp higher than that of aBMD.
Evaluation of Clinical Accuracy
The issue of how to compare the clinical performance of these
predictors for hip fracture risk assessment is complex. There
are two different questions that need to be answered:
a) For a given predictor, given a group of patients, somewho
at the time of enrolment already had a hip fracture, and
some who at the same time did not, how accurately can
the predictor separate the fractured patients and non-
fractured ones? This will be referred to hereinafter as dis-
crimination accuracy.
b) Given a group of patients at risk but who initially had no
hip fractures, how accurate can each predictor identify
those patients who experienced a hip fracture within the
1 Hereinafter, we will use the % symbol to indicate the percent ratio between
the value of interest and some average value that can be used to normalise it.
Vice versa, we will use percentage point (annotated with the symbol pp) to
indicate difference in percentage between two normalised values.
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following 5 or 10 years after the DXA and QCT exami-
nation were performed? This will be referred to hereinaf-
ter as prediction accuracy.
If the clinical use case involves the evaluation of a relative
change in strength between two or more controls of the same
subject at different time points, what matters is the discrimi-
nation accuracy. If the clinical use case is to predict the abso-
lute risk of fracture, the question is whether the strength as
predicted today can inform what happens tomorrow; this also
involves the progression of the disease over time.
Following this logic, discrimination accuracy could be
evaluated with data collected with cross-sectional studies
[26, 27], while prediction accuracy would require data from
longitudinal studies where patients are scanned at baseline and
then followed-up for years [6, 7, 9, 10]. However, because of
the modest incidence of hip fractures in the general popula-
tion, longitudinal studies are very difficult and expensive to
conduct and rarely produce well-paired fractured/control co-
horts over age, height, and weight. Also, the odds ratios for the
DXA-aBMD predictor reported in previous cross-sectional
studies are in the same range of those obtained from longitu-
dinal studies. This suggests that DXA-aBMD and QCT-SSFE
strength are both predictors of the absolute risk of fracture at 5
(ARF5) or 10 years (ARF10). Thus, it seems plausible to
evaluate DXA-aBMD and QCT-SSFE prediction accuracy al-
so with data from cross-sectional studies.
Even cross-sectional studies have their own limitations.
The most important is that a predictor cannot be calculated
for the fractured hip; normally the predictor value for the
controlateral intact hip is used instead. Of course, this is an
additional potential source of bias; while on average such
differences as mechanically negligible, in some random cases
differences can be significant [28].
Discrimination Accuracy of DXA-aBMD vs QCT-SSFE
The ISCD 2015 paper reached the conclusion that QCT-SSFE
strength is not significantly better than DXA-aBMD in
predicting hip fractures on the basis of five studies [6–10].
All these studies do have some methodological limitations,
when compared to the current state of the art.
Firstly, all these studies used Cartesian meshes, where
each voxel of the QCT 3D image is converted into a
hexahedral finite element. While Cartesian mesh offers
many advantages, it is unquestionably less accurate in
predicting stresses and strains than modelling methods
that use smooth meshes obtained from segmented CT im-
ages [29, 30]. How much this loss of accuracy impacts on
the accuracy of strength prediction depends on a number
of factors, with the most important ones being the consti-
tutive equation and failure criterion [18, 31].
Secondly, all five studies used proximal femur QCT scans,
limited to the metaphyseal and epiphyseal portions of the fe-
mur. A recent study has shown that this may introduce uncer-
tainties in the anatomical orientation of the femur, thusmaking
it difficult to reproducibly define the loading directions if not
properly corrected using additional atlas information [12••].
Thirdly, three of the studies that supported ISCD conclu-
sions [6, 7, 9] used only a single loading direction to predict
the strength under side-fall conditions; one [8] used three, and
the other [10] used eight. A study published in 2014, but not
included in the ISCD review [11••], confirmed that a single-
load side fall strength predicted by QCT-SSFE was not signif-
icantly more accurate than DXA-aBMD. But when the mini-
mum strength under side-fall conditions (MSS) out of 10 sim-
ulated fall directions was used instead, QCT-SSFE yielded a
significant improvement over DXA-aBMD [11••]. In this
study, the improvement was quite dramatic: in a cohort of 22
fractures and 33 controls, they found that the total femoral
DXA-aBMD Area under the ROC curve (AUC) was 0.79,
that of single-load QCT-SSFE was 0.77, but that of multiple-
load QCT-SSFE was 0.88. One limitation of this study was
that fracture and control groups were not age-matched; when
the same approach was used on a larger cohort pair-matched
for age, height, and weight, the AUC of DXA-aBMD was
found to be 0.75 and 0.79 with multiple-load QCT-SSFE
[12••]. Lastly, the strength predicted by QCT-SSFE in side-
fall has been recently reported to be highly sensitive to how
precisely the impact force is modelled [32].
When all these improvements are included, the conclusions
of the ISCD 2015 paper are indeed reversed. Recently, we
evaluated the discrimination accuracy of the Insigneo CT2S
modelling technology, that includes smooth-boundary
meshes, anatomical orientation, 33 different side-fall direc-
tions, and refined non-linear boundary conditions on a retro-
spective cohort of postmenopausal women, formed by 50
cases of fragility hip fracture and 50 cases of controls (no
fractures), pair-matched by age, weight, and height [27] (here-
inafter referred as Sheffield Cohort) [33]. The AUC for the
side-fall strength predicted by the QCT-SSFE model was
0.82, while that of aBMD was 0.75; thus, QCT-SSFE can
separate fractured and non-fractured cases with an accuracy
that is 7 pp higher than that of aBMD.
Prediction Accuracy of DXA-aBMD vs QCT-SSFE
When these strength predictors are used not to classify, but to
predict who is at risk, the definition of accuracy is immediate as
soon as one has defined for each predictor a threshold value
above/below which fracture is assumed to occur. Setting a
threshold for DXA-aBMD is complex. However, if we use T-
score based on DXA-aBMD, the WHO recommends an inter-
vention if the T-score is equal of lower than − 2.5. For QCT-
SSFE strength no such consensus is available. In a study on
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North American men, Orwoll et al. found all hip fractures oc-
curred for a QCT-SSFE MSS strength of 2900 N or lower [6].
Based on this, Keaveny et al. proposed 3000 N as a threshold
value [34]. This value was also used in a recent cost-
effectiveness study on QCT-SSFE [35••]. Considering the gen-
der differences, such threshold should probably be normalised
for the average body weight that for North-Americans is
80.7 Kg [36]; this yields a threshold value of four-times the
body weight (BW). When these thresholds were used on the
Sheffield Cohort, we found a prediction accuracy of 66% for
the T-score based on DXA-aBMD, and 73% for theMSS based
on QCT-SSFE. So, again QCT-SSFE is 7 pp more accurate
than DXA-aBMD. MSS prediction accuracy was reduced to
69% when the analysis was restricted to osteopenic patients.
Comparison of Cost, Risk, and Complexity
Between the Methods
Assuming these most recent implementations of QCT-SSFE
technologies provide discrimination and prediction accuracies
7 pp better than DXA-aBMD, is this improvement sufficient
to justify the higher risks involved with the higher costs, the
higher radiation dose and the higher organisational complexity
involved?
Cost
The cost of medical imaging varies considerably depending
on the country, the healthcare provision model, etc. As we are
interested to make a comparison in relative terms, here only
official costs provided by the UK National Health Service
(NHS) are used. Regarding the cost of the QCT-SSFE analysis
service, we were able to recover this information only for two
on-line services that provide QCT-SSFE modelling: the
VirtuOst service provided by O. N. Diagnostics Inc.2 and the
CT2S service provided by the Insigneo institute.3 The first is
FDA-approved for clinical use, while the second can currently
be used only for research. Currently for its clinical services, O.
N. Diagnostics charges a cost for the BMD part of its test that
is equivalent to the cost of a DXA exam, and provides the
FEA analysis for free. The cost for FEA is not yet established
but is expected to eventually be supported by clinical cost-
effectiveness (Prof Tony Keaveny, personal communication).
The CT2S service is tentatively priced to £250 per analysis,
with a discount of 50% for non-sponsored studies run by not-
for-profit organisations; here we will use the CT2S service
figures as cost estimate. Assuming the use of non-reported
imaging, the cost difference between DXA-aBMD and
QCT-SSFE is £266 in UK (Table 1).
Adding £189 for the endocrinology visit (source: NHS of-
ficial costs 2016/17), the total risk assessment costs are £251
for the DXA-aBMD pathway, and £522 for the QCT-SSFE
pathway. It is assumed that a risk assessment visit is conducted
every 2 years for all patients. In addition, it is also assumed the
cost is £7200 for the pharmacological prevention (£60 per
2 http://ondiagnostics.com
3 https://ct2s.sheffield.ac.uk
Table 2 Comparative use of QCT-SSFE and aBMD as a strength
predictor in a clinical study. In order to detect a 20% difference in
strength between two interventions, with significance level α = 0.05 and
statistical power β = 80%, 245 patients need to be enrolled when using
aBMD, while only 127 patients need to be enrolled when using QCT-
SSFE
%SEE aBMD QCT-SSFE
75% 82%
Average femoral strength (N) 3265 3265
Standard deviation of the predictor (N) 3054 2199
% difference in strength to be detected 20% 20%
α-error 0.05 0.05
□-power 80% 80%
Number of patients per group 123 64
Total number of patients in the study 246 128
Fixed costs for trial (£5000 patient) £1,230,000.00 £640,000.00
Cost of imaging (£62 DXA; £78 CT) £15,252.00 £9984.00
Cost of simulation (£250) £- £32,000.00
Total cost £1,245,252.00 £681,984.00
In summary, only 127 patients are required to see differences of 20% in
strength (statistically significant) between interventions with QCT-SSFE,
in comparison to 245 patients using aBMD. While QCT-SSFE is more
expensive than aBMD, the significant reduction in the cohort size will
reduce the total cost of the trial. The key value is the fixed cost per patient,
which in Table 2 is assumed to be £5000. According to a recent report in
the Pharmaceutical Research and Manufacturers of America commis-
sioned to Battelle, the average value is US$36,500 among trials of any
phase or condition. Therefore, our assumption is relatively conservative.
6 https://tinyurl.com/Batelle-report
Table 1 Costs of DXA and CT
from the official costing of the
UK NHS; QCT-SFFE simulation
service cost from the CT2S
service
Exam HRG code 2016–2017 tariff
(unbundled, without
reporting)
DEXA RA15Z £62
Computerised tomography scan, one area, no contrast,
19 years and over
RA08A £78
QCT-SSFE analysis service NA £250
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month per 10 years, Alendronic acid 70 mg tablets. Source:
NHS Electronic Drug Tariff Jan 2018), £16,302 for the direct
cost associated to a hip fracture [37], and £10,364 for the
indirect costs [38]. In order to calculate the incremental cost-
effectiveness ratio (ICER), we assumed an average quality-
adjusted life year (QALY) of 0.91 for women over 55 with
no fractures and 0.63 with a hip fracture [39].
Radiation Dose
The average effective radiation dose typically associated to a
DXA exam is 0.001 mSv, whereas that of standard pelvis CT
is 6 mSv. However, several measures can be adopted to reduce
this effective dose. The whole femur CT scan protocol recom-
mended by the CT2S service4 involves an effective radiation
dose in the range of 1.9–4.8 mSv for males and 1.3–3.2 mSv
for females. A recent study on the effect of reducing the X-ray
energy on the predictive accuracy of QCT-SSFE of vertebral
bodies suggests that even more aggressive reductions can be
adopted without any significant loss of predictive accuracy [40].
Organisational Impact
For both CT2S and VirtuOst, the organisational impact in-
volved with these services is minimal. The radiographer sub-
mits the DICOM files to the remote on-line service, and QCT-
SSFE strength report is returned, typically via an email, in a
time frame comparable to a standard radiology report (24–
48 h). Assuming all this requires 10 min of an NHS grade 7
radiographer; this would cost approximately £8 per case.
Appropriateness of QCT-SSFE in Clinical Research
and Practice
Clinical Studies with Femoral Strength as Endpoint
It is common to conduct clinical studies where an intervention
(physical or pharmacological) is evaluated against another in-
tervention or the lack of thereof (i.e. placebo in the case of
drug intervention), using bone strength as end point. Given its
superior predictive accuracy, is it convenient to use QCT-
SSFE in place of DXA-aBMD for strength estimation?
The first issue is the ethics involved with the use of higher
radiation dose in a study for research purposes. This is a de-
cision taken case by case by the local research ethics commit-
tee. However, considering a typical cohort of women over
50 years of age, these subjects have a general population risk
of 2.8% of death related to a hip fracture [41]. If QCT-SSFE
increases our ability to identify subjects at risk by 7 pp,
0.196% of the patients at risk of death for hip fracture would
be treated instead. Considering current interventions avoid
fractures in at least 40% of those who are treated [42],
switching to QCT-SSFE would reduce the risk of death for
complications associated to hip fracture by 0.0784%. Standard
risk calculations5 suggest that a pelvic CT with an effective
dose of 3.8 mSv would increase the risk of cancer by
0.0154%. Considering that the average mortality for cancer
is 52%, the risk of death due the additional radiation could be
estimated to increase by 0.0080%, which is much lower than
the risk reduction QCT-SSFE seems to offer.
The second issue is the feasibility of the study, in relation to
recruitment limits imposed by temporal, financial, operational
4 https://ct2s.sheffield.ac.uk/static/CT2SApp/multisim/CT2S_CTScan_
Protocol.pdf 5 http://www.xrayrisk.com
Table 3 Cost–benefit analysis of
DXA-based T-score and QCT-
SSFE pathways. We assumed
sensitivity and specificity for both
T-score and QCT-SSFE strength
from the results for the Sheffield
cohort reported above, and
efficacy of treatment 40%
DXA-T-score QCT-SSFE Dual pathway
Number of patients referred to secondary care 1000 1000 1000
Patients considered at risk and treated 367 602 633
Patients not treated 633 398 286
Patients who fracture under treatment 147 241 253
Patients who fracture without treatment 316 199 143
Total patients who fracture 463 440 396
Risk assessment costs £1,255,000 £2,610,000 £1,899,184
Preventive pharma treatment cost £2,644,898 £4,334,694 £4,555,102
Costs of hip fracture treatment (direct) £7,552,151 £7,169,553 £6,454,261
Total cost hip fractures (direct costs) £11,452,049 £14,114,247 £12,908,547
Costs of hip fracture treatment (indirect) £4,801,282 £4,558,045 £4,103,298
Total cost hip fractures (total cost of care) £16,253,331 £18,672,292 £17,011,845
Direct costs saved × 1000 patients £- -£2,662,197.96 -£1,456,497.96
Full costs saved × 1000 patients £- -£2,418,961.22 -£758,514.29
Fractures avoided by new pathway – 23 67
Negative values in italic
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or ethical constraints. Since QCT-SSFE predicts strengthmore
accurately than aBMD, a simple statistical power calculation
can be used to estimate the difference in cohort size that this
improvement in accuracy would bring. The full detail of the
calculations is provided in Table 2.
QCT-SSFE as Clinical Tool to Assess the Risk of Hip Fracture
With respect to this second use case, the risk–benefit
analysis done for the first use case in relation to the
increase in radiation dose, remains valid. Thus, the op-
portunity to adopt the strength predicted by QCT-SSFE
models in place of the T-score measured with DXA
needs to be seen entirely from a cost–benefit point of
view. To this purpose, the costs were estimated based
on a scenario of managing 1000 patients, who have
been considered at risk of osteoporosis, referred to a
secondary care specialist for 10 years, with three alter-
native clinical pathways (Table 3).
In the first pathway, all patients who are osteoporotic ac-
cording to the WHO definition (T-score ≤ − 2.5) are treated. In
the second, all patients whose MSS ≤ 2551 N are treated. In
the third (hereinafter called dual pathway), patients with T-
score ≤ − 2.5 are treated; those with T-score > − 1.0 are not
treated. Patients with − 2.5 < T-score ≤ − 1.0 are provided with
further examination using the QCT-SSFE, and patients with
MSS ≤ 2551N are also treated. The percentage of patients that
fall in each of these categories from the Sheffield Cohort was
derived.
The use of QCT-SSFE as a risk predictor would al-
ways increase the costs and reduce the number of hip
fractures. The QCT-SSFE pathway would involve a cost
per QALY gained of £368,102, while the dual pathway
would require a cost increase of £40,224 per QALY
gained, which is considered not cost-effective according
to the NICE thresholds. However, if we could reduce
the cost of the simulation to £75 (~ US$100), the cost
increase per QALY gained would be reduced to
£14,656, which is considered cost-effective in most pub-
lic healthcare systems.
Discussion
This study revised the available literature to date comparing
the accuracy of DXA-aBMD and QCT-SSFE in predicting
bone strength measured experimentally on cadaver bones, as
well as their clinical accuracy both in terms of discrimination
and prediction. Based on this information, and the results ob-
tained using a state-of-the-art QCT-SSFE technology called
CT2S on a retrospective pair-matched cohort, some basic
cost-effectiveness calculations were performed to explore the
use of QCT-SSFE instead of DXA-aBMD in (a) clinical
studies with femoral strength as endpoint, (b) predictor of
the risk of hip fracture in low bone mass patients. We conclud-
ed that QCT-SSFE is always preferable over DXA-aBMD in
clinical studies with femoral strength as the endpoint, while it
is not yet cost-effective as a hip fracture risk predictor, al-
though pathways that combine both QCT-SSFE and DXA-
aBMD are promising.
Several recent studies conducted by different research
groups using different QCT-SSFE technologies all indicate
that QCT-SSFE is 6–7 pp more accurate than DXA-based
aBMD (or T-score) in predicting femoral strength, in classify-
ing fractured and non-fractured patients, and in predicting the
risk of hip fracture.
In clinical trials using femoral strength as endpoint to eval-
uate the efficacy of an intervention in reducing the risk of hip
fracture, this increase in accuracy can reduce as much as 50%
of the cohort size that is required to recognise as statistically
significant (p < 0.05) with 80% power, differences in strength
between the two interventions being tested of 20% or greater.
This involves additional cost for imaging and simulation,
which are however offset by the reduction in the number of
patients enrolled, and the associated fixed costs. In the light of
these results, it is recommended to use QCT-SSFE as predictor
of femoral strength in any clinical trial that uses strength as
end point, instead of aBMD.
When the use of these predictors to support the decision to
treat in secondary care settings was considered, a preliminary
cost-benefit analysis suggested that a widespread adoption of
QCT-SFFEwould not be cost-effective. At the current cost for
the CT2S service (£250), the use of QCT-SSFE on osteopenic
cases only (dual pathway) is also not cost-effective. However,
a recent cost-effectiveness study based on a state-transition
microsimulation suggests that the combination of aBMD
and QCT-SSFE is cost-effective, when the cost of simulation
is assumed to be US$100 (~ £75) [35••]. Indeed, if we used
that simulation cost, the dual pathway would become cost-
effective.
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